Webcasts
![Play](https://www.pcsk9forum.org/wp-content/themes/pcsk9forumnew/images/presentation.png)
How much do you have to reduce Lp(a) to achieve significant clinical benefit?
![Play](https://www.pcsk9forum.org/wp-content/themes/pcsk9forumnew/images/presentation.png)
Bempedoic acid: The new kid on the block
![Play](https://www.pcsk9forum.org/wp-content/themes/pcsk9forumnew/images/presentation.png)
Immunotherapies in homozygous FH: Alirocumab and evinacumab
![Play](https://www.pcsk9forum.org/wp-content/themes/pcsk9forumnew/images/presentation.png)
Remnant lipoproteins and impact of PCSK9 inhibition
![Play](https://www.pcsk9forum.org/wp-content/themes/pcsk9forumnew/images/presentation.png)
Genome-wide polygenic risk scores: Insights from ODYSSEY OUTCOMES
![Play](https://www.pcsk9forum.org/wp-content/themes/pcsk9forumnew/images/presentation.png)
Genetic risk scores: How much do they add?
![Play](https://www.pcsk9forum.org/wp-content/themes/pcsk9forumnew/images/presentation.png)
Inclisiran: Update on efficacy, dosing regimen, safety and COVT trial
![Play](https://www.pcsk9forum.org/wp-content/themes/pcsk9forumnew/images/presentation.png)
Lp(a): Findings in ODYSSEY OUTCOMES
![Play](https://www.pcsk9forum.org/wp-content/themes/pcsk9forumnew/images/presentation.png)
What’s new in very high-risk patients?
![Play](https://www.pcsk9forum.org/wp-content/themes/pcsk9forumnew/images/presentation.png)
Do the new ESC/EAS guidelines change your clinical practice? Acute coronary syndromes
![Play](https://www.pcsk9forum.org/wp-content/themes/pcsk9forumnew/images/presentation.png)
Lp(a): Risk factor or causal factor? A critical appraisal
![Play](https://www.pcsk9forum.org/wp-content/themes/pcsk9forumnew/images/presentation.png)
ODYSSEY OUTCOMES and stroke events
![Play](https://www.pcsk9forum.org/wp-content/themes/pcsk9forumnew/images/presentation.png)
Treat ischaemic stroke to target
![Play](https://www.pcsk9forum.org/wp-content/themes/pcsk9forumnew/images/presentation.png)
Endothelial LDL transcytosis in atherosclerosis
![Play](https://www.pcsk9forum.org/wp-content/themes/pcsk9forumnew/images/presentation.png)
Emerging lipid science: ApoE and chronic disease
![Play](https://www.pcsk9forum.org/wp-content/themes/pcsk9forumnew/images/presentation.png)
ODYSSEY OUTCOMES: Update
![Play](https://www.pcsk9forum.org/wp-content/themes/pcsk9forumnew/images/presentation.png)
New data from FOURIER and design of the VESALIUS-CV Trial
![Play](https://www.pcsk9forum.org/wp-content/themes/pcsk9forumnew/images/presentation.png)
PCSK9 Genetics: New Insights
![Play](https://www.pcsk9forum.org/wp-content/themes/pcsk9forumnew/images/presentation.png)
![Hepatic lipid metabolism: Storage vs secretion](https://www.pcsk9forum.org/wp-content/uploads/Jan-Borén-small-1.jpg)
Jan Boren
Hepatic lipid metabolism: Storage vs secretion
![Play](https://www.pcsk9forum.org/wp-content/themes/pcsk9forumnew/images/presentation.png)
![Using naturally randomized genetic evidence to estimate the clinical benefit of lowering triglyceride-rich lipoproteins](https://www.pcsk9forum.org/wp-content/uploads/Brian-A-Ference-150x150.jpg)
Using naturally randomized genetic evidence to estimate the clinical benefit of lowering triglyceride-rich lipoproteins